title: Nonresolving inflammation in gp91phox-/- mice, a model of human chronic granulomatous disease, has lower adenosine and cyclic adenosine 5'-monophosphate.
abstract: In chronic granulomatous disease (CGD), there is failure to generate reactive oxygen metabolites, resulting in recurrent infections and persistent inflammatory events. Because responses to sterile stimuli in murine models of CGD also result in nonresolving inflammation, we investigated whether defects in endogenous counterregulatory mechanisms and/or proresolution pathways contribute to the etiology of CGD. To this end, we conducted a series of experiments finding, in the first instance that adenosine and cAMP, which dampen innate immune-mediated responses, show a biphasic profile in resolving peritonitis; peaking at onset, waning as inflammation progresses, and rising again at resolution. We also found elevations in adenosine and cAMP in resolving human peritonitis. In gp91(phox-/-) mice, an experimental model of CGD, levels of adenosine and cAMP were significantly lower at onset and again at resolution. Corroborating the finding of others, we show that adenosine, signaling through its A(2A) receptor and therefore elevating cAMP, is not only anti-inflammatory, but, importantly, it does not impair proresolution pathways, properties typical of nonsteroidal anti-inflammatory drugs. Conversely, antagonizing the A(2A) receptor worsens acute inflammation and prolongs resolution. Taking this further, activating the A(2A) receptor in gp91(phox-/-) mice was dramatically anti-inflammatory regardless of the phase the inflammatory response A(2A) agonists were administered, i.e., onset or resolution, demonstrating wide and robust pharmacological flexibility that is unlikely to subvert proresolution pathways. Therefore, we describe the biphasic profile of adenosine and cAMP throughout the time course of acute inflammation that is dysregulated in CGD.
authors.affiliation: Department of Experimental Medicine and Translational Therapeutics, William Harvey Research Institute, London, United Kingdom.
authors.forename: Ravindra
authors.initials: R
authors.lastname: Rajakariar
authors.forename: Justine
authors.initials: J
authors.lastname: Newson
authors.forename: Edwin K
authors.initials: EK
authors.lastname: Jackson
authors.forename: Precilla
authors.initials: P
authors.lastname: Sawmynaden
authors.forename: Andrew
authors.initials: A
authors.lastname: Smith
authors.forename: Farooq
authors.initials: F
authors.lastname: Rahman
authors.forename: Muhammad M
authors.initials: MM
authors.lastname: Yaqoob
authors.forename: Derek W
authors.initials: DW
authors.lastname: Gilroy
mesh_terms: D000208:Acute Disease; D000241:Adenosine / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000502:physiology; D000818:Animals; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000502:physiology; D004195:Disease Models, Animal; D006105:Granulomatous Disease, Chronic / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007249:Inflammation / Q000201:enzymology / Q000276:immunology / Q000378:metabolism*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D007970:Leukopenia / Q000473:pathology / Q000628:therapy; D008562:Membrane Glycoproteins / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D000074662:NADPH Oxidase 2; D019255:NADPH Oxidases / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D010538:Peritonitis / Q000201:enzymology / Q000276:immunology / Q000628:therapy
chemical_list: D018836:Inflammation Mediators; D008562:Membrane Glycoproteins; D000242:Cyclic AMP; C488842:Cybb protein, mouse; D000074662:NADPH Oxidase 2; D019255:NADPH Oxidases; D000241:Adenosine